Seminars in Oncology
Volume 34 , Pages S7-S11 , April 2007

Developing Strategies for Liver Metastases From Colorectal Cancer

  • René Adam

      Affiliations

    • Corresponding Author InformationAddress reprint requests to René Adam, MD, PhD, Hôpital Paul Brousse, C.H.B., 14 Avenue Paul Vaillant Couturier, Villejuif 94800, France.
    • Dr Adam has received research grant support from sanofi-aventis.

References 

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  2. International Agency for Research on Cancer: GLOBOCAN 2002 data. Available at: http://www-dep.iarc.fr (accessed November 16, 2006)
  3. Stangl R, Altendorf-Hofman A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1404–1410
  4. LiverMetsSurvey. International registry of liver metastases of colorectal cancer. Available at: http://www.livermetsurvey.org (accessed July 2006)
  5. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–766
  6. Abdalla EK, Vauthey J-N, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–827
  7. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–318
  8. In:  Nordlinger B,  Jaeck D editor. Traitment de metastases hépatiques as cancers colorectaus. Paris: Springer-Verlag; 1992;
  9. Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery. 1994;116:703–711
  10. Minagawa M, Maltuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: Long-term results. Ann Surg. 2000;231:487–499
  11. Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for multiple colorectal metastases: Influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival. Arch Surg. 2002;137:1187–1192
  12. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg. 1990;77:1241–1246
  13. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg. 2004;240:644–658
  14. Rogers MS, McCall JL. Surgery for colorectal liver metastases with hepatic lymph node involvement: A systematic review. Br J Surg. 2000;87:1142–1155
  15. Regnard JF, Grunenwald D, Spaggiari L, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg. 1998;66:214–218
  16. Thirion P, Wolmark N, Haddad E, et al. Meta-Analysis Group in Cancer Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: A re-analysis of 1458 non-operable patients randomized in 22 trials and 4 meta-analyses. Ann Oncol. 1999;10:1317–1320
  17. Hobday TJ, Kugler JW, Mahoney MR, et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: A North Central Cancer Treatment Group review. J Clin Oncol. 2002;20:4574–4580
  18. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663–669
  19. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–1319
  20. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol. 2001;8:347–353
  21. Alberts SR, Horvath WL, Sterfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243–9249
  22. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer; a randomized GERCOR study. J Clin Oncol. 2004;22:229–237
  23. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933–939
  24. Ducreux M, Köhne C-H, Schwartz GK, et al. Irinotecan in metastatic colorectal cancer: Dose intensification and combination with new agents, including biological response modifiers. Ann Oncol. 2003;14:ii17–ii23
  25. Ychou M, Conroy T, Seitz JF, et al. An open phase I study assessing the feasibility of the triple combination: Oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2003;14:481–489
  26. Falcone A, Masi G, Cupini S, et al. Surgical resection of metastases after biweekly chemotherapy with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI) in initially unresectable metastatic colorectal cancer. [abstract 3553] Proc Am Soc Clin Oncol. 2004;22:14S
  27. Quenet F, Nordlinger B, Rivoire M, et al. Resection of previously unresectable liver metastases from colorectal cancer after chemotherapy with CPT11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. [abstract 3613] Proc Am Soc Clin Oncol. 2004;23:273
  28. Abad A, Antón A, Massuti B, et al. TTD Spanish Group Resectability of liver metastases in patients with advanced colorectal cancer after treatment with the combination of oxaliplatin, irinotecan, and 5FU (Final results of a phase II study). [abstract 3618] J Clin Oncol. 2005;23:16S
  29. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR) (Preliminary results). [abstract 3512] Proc Am Soc Clin Oncol. 2004;23:248
  30. Cervantes A. Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: A phase II study. Eur J Cancer Suppl. 2005;3:181–182(poster)
  31. Adam R, Pascal G, Azoulay D, et al. Liver resection for colorectal metastases: The third hepatectomy. Ann Surg. 2003;238:871–883
  32. Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90:963–969
  33. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy–An Intergroup study. J Clin Oncol. 2002;20:1499–1505
  34. Adam R. Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol. 2003;14(suppl 2):ii13–ii16
  35. Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases: Association Francaise de Chirurgie. Br J Surg. 1997;84:977–980
  36. Scheele J, Stangl R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71

PII: S0093-7754(07)00019-X

doi: 10.1053/j.seminoncol.2007.01.003

Seminars in Oncology
Volume 34 , Pages S7-S11 , April 2007

Article Tools

* Image Usage & Resolution